USPTO website indicates a non-final office action was issued for NGIO’s mark “Complete Vaccine” by the examiner on or about April 23, 2021. Typically, an applicant has 6 months to respond to an office action or the application lapses. Since a mark must be used in commerce, I would suspect this is the issue raised by the examiner in his or her office action. Since Generex has engaged a firm to shepherd the vaccine, so to speak, and since the trademark application is still live, it would appear that the company management, though currently silent, believes they will have a vaccine by late October.